Refractive correction and patching improve VA in amblyopia

Article

Refractive correction and patching improves visual acuity in amblyopic eyes.

Refractive correction and patching improves visual acuity in amblyopic eyes, according to a paper in the Archives of Ophthalmology.

Dr Yi Pang et al., Illinois College of Optometry, Chicago, Illinois, USA, looked at 17 amblyopic children. The patients were aged between 4 and 14 years and has amblyopia linked to myopic anisometropia.

Visual acuity (VA) was evaluated at 4, 8, 12 and 16 weeks whilst all patients wore spectacles and/or contact lenses for complete refractive correction. At 16 weeks all patients underwent patching.

Mean baseline VA in amblyopic eyes improved from 0.96 logMAR to 0.84 logMAR with refractive correction and a mean of 0.71 logMAR with additional patching. The findings demonstrated an improvement of 2.59 lines when comparing baseline VA and final VA.

Final VA was linked to baseline VA, magnitude of anisometropia and the patching compliance level. The improvement in VA was linked to patient age and presence of eccentric fixation.

Overall, 88% of patients experienced an improvement of 2 lines or more and a further improvement was discovered when patching was applied to patients who underwent refractive correction.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.